Asset Details
Do you wish to reserve the book?
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Do you wish to request the book?
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
2015
Overview
In two randomized trials, evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9), reduced LDL cholesterol levels by 61%. In an exploratory analysis, the incidence of cardiovascular events was reduced in the evolocumab group.
Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of major cardiovascular events in numerous large outcome trials.
1
–
3
For this reason, LDL cholesterol reduction has been incorporated into practice guidelines as a fundamental means of reducing cardiovascular morbidity and mortality.
4
–
7
During the past 3 years, monoclonal antibodies that inhibit proprotein convertase subtilisin–kexin type 9 (PCSK9) have emerged as a new class of drugs that very effectively lower LDL cholesterol levels.
8
One of the members of this class is evolocumab, a fully human monoclonal antibody that typically achieves approximately a 60% reduction . . .
Publisher
Massachusetts Medical Society
Subject
/ Angina
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Anticholesteremic Agents - adverse effects
/ Anticholesteremic Agents - therapeutic use
/ Cardiovascular Diseases - epidemiology
/ Cardiovascular Diseases - prevention & control
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Hypercholesterolemia - blood
/ Hypercholesterolemia - drug therapy
/ Ischemia
/ Kexin
/ Lipids
/ Male
/ Stroke
